恶性胸腔积液蛋白质组学研究进展  

Recent advances in proteomics analysis of malignant pleurai effusions

作　　者：生淑红[1] 朱惠莉[1] 

机构地区：[1]复旦大学附属华东医院呼吸内科,上海200020

出　　处：《国际呼吸杂志》2008年第6期379-381,共3页International Journal of Respiration

摘　　要：恶性胸腔积液是肿瘤患者常见的临床问题，研究恶性胸腔积液中的蛋白质是否可以用来作为肺癌及其他相关疾病的诊断标志物很有意义。蛋白质组学的出现拓宽了人们的视野并加快了医学研究进展，如今蛋白质组学的研究方法在生物标志物的鉴定乃至肿瘤发生机制的探索中担当重要角色，蛋白质组学技术的迅猛发展为全面有效地分析恶性胸腔积液的蛋白质组分提供了技术支持，本文对近年蛋白质组学技术发展及恶性胸腔积液蛋白质组学研究进展进行综述。Malignant pleural effusions are a common clinical problem in the patients with neoplastic disease. It is of interest to investigate whether proteins in malignant pleural effusion can be used as markers for diagnosis of lung cancer and other relative diseases. The introduction of proteomics has been greatly broadening people＇s view and accelerating the path in various medical researches. Proteomic methods play an important role in identifying biomarkers and gaining deep insights into pathogenesis of cancer. The rapid development of proteomic techniques has provided a great opportunity to analyze the protein composition of malignant pleural effusions comprehensively and effectively. This review describes developments in proteomic technology and discusses recent advances in proteomics analysis of malignant pleural effusions.

关 键 词：恶性胸腔积液 蛋白质组学 生物标志物 

分 类 号：R730[医药卫生—肿瘤]